| Year |
Citation |
Score |
| 2020 |
Higgins KA, Simone CB, Amini A, Chetty IJ, Donington J, Edelman MJ, Chun SG, Kestin LL, Movsas B, Rodrigues GB, Rosenzweig KE, Slotman BJ, Rybkin II, Wolf A, Chang JY. American Radium Society™ , Appropriate Use Criteria on Radiation Therapy for Extensive-stage Small Cell Lung Cancer. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. PMID 33011389 DOI: 10.1016/j.jtho.2020.09.013 |
0.312 |
|
| 2019 |
Rice SR, Vyfhuis MAL, Scilla KA, Burrows WM, Bhooshan N, Suntharalingam M, Edelman MJ, Feliciano J, Badiyan SN, Simone CB, Bentzen SM, Feigenberg SJ, Mohindra P. Insurance Status is an Independent Predictor of Overall Survival in Patients With Stage III Non-small-cell Lung Cancer Treated With Curative Intent. Clinical Lung Cancer. PMID 31708388 DOI: 10.1016/J.Cllc.2019.08.009 |
0.34 |
|
| 2019 |
Edelman MJ, Redman MW, Albain KS, McGary EC, Rafique NM, Petro D, Waqar SN, Minichiello K, Miao J, Papadimitrakopoulou VA, Kelly K, Gandara DR, Herbst RS. Brief Report: SWOG S1400C (NCT02154490)-A Phase II Study of Palbociclib for Previously Treated Cell Cycle Gene Alteration Positive Patients with Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-study). Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. PMID 31302234 DOI: 10.1016/J.Jtho.2019.06.027 |
0.319 |
|
| 2019 |
Reckamp KL, Akerley W, Edelman MJ, Halmos B, He K, Johnson M, Mudad R, Neal JW, Owonikoko TK, Patel JD, Patel SP, Riess JW, Sacher AG, Turcotte S, Villaruz LC, et al. Abstract CT225: A Phase Ib/IIa randomized pilot study to investigate the safety and tolerability of autologous T-cells with enhanced T-cell receptors specific to NY-ESO-1/LAGE-1a (GSK3377794) alone, or in combination with pembrolizumab, in advanced non-small cell lung cancer Cancer Research. 79. DOI: 10.1158/1538-7445.Am2019-Ct225 |
0.304 |
|
| 2018 |
Stinchcombe TE, Fan W, Schild SE, Vokes EE, Bogart J, Le QX, Thomas CR, Edelman M, Horn L, Komaki R, Cohen HJ, Ganti AK, Pang H, Wang X. A pooled analysis of individual patient data (IPD) of concurrent chemoradiotherapy for limited-stage small cell lung cancer (LS-SCLC) in elderly compared to younger patients (pts) who participated in US National Cancer Institute cooperative group studies. Annals of Oncology : Official Journal of the European Society For Medical Oncology. 29: viii597-viii598. PMID 32137590 DOI: 10.1093/annonc/mdy298.004 |
0.304 |
|
| 2018 |
Stinchcombe TE, Fan W, Schild SE, Vokes EE, Bogart J, Le QT, Thomas CR, Edelman MJ, Horn L, Komaki R, Cohen HJ, Kishor Ganti A, Pang H, Wang X. A pooled analysis of individual patient data from National Clinical Trials Network clinical trials of concurrent chemoradiotherapy for limited-stage small cell lung cancer in elderly patients versus younger patients. Cancer. PMID 30343497 DOI: 10.1002/cncr.31813 |
0.312 |
|
| 2018 |
Feliciano JL, Le-Rademacher JG, Gajra A, Edelman MJ, Zemla T, McMurray R, Chen H, Hurria A, Muss H, Cohen HJ, Lilenbaum R, Jatoi A. Do older patients with non-small cell lung cancer also benefit from first-line platinum-based doublet chemotherapy? Observations from a pooled analysis of 730 prospectively-treated patients (Alliance Study A151622). Journal of Geriatric Oncology. PMID 29848457 DOI: 10.1016/j.jgo.2018.05.006 |
0.321 |
|
| 2018 |
Vyfhuis MAL, Burrows WM, Bhooshan N, Suntharalingam M, Donahue JM, Feliciano J, Badiyan S, Nichols EM, Edelman MJ, Carr SR, Friedberg J, Henry G, Stewart S, Sachdeva A, Pickering EM, et al. Implications of Pathologic Complete Response Beyond Mediastinal Nodal Clearance With High-Dose Neoadjuvant Chemoradiation Therapy in Locally Advanced, Non-Small Cell Lung Cancer. International Journal of Radiation Oncology, Biology, Physics. PMID 29559292 DOI: 10.1016/j.ijrobp.2018.02.003 |
0.338 |
|
| 2018 |
Mohindra P, Vyfhuis M, Scilla K, Feliciano J, Edelman M, Burrows W, Badiyan S, Suntharalingam M, Feigenberg S, Simone C. P1.17-10 Consolidation Chemotherapy in Stage III Non-Small Cell Lung Cancer: Still a Critical Piece of the Puzzle Journal of Thoracic Oncology. 13: S658. DOI: 10.1016/j.jtho.2018.08.1043 |
0.327 |
|
| 2017 |
Vyfhuis MAL, Bhooshan N, Molitoris J, Bentzen SM, Feliciano J, Edelman M, Burrows WM, Nichols EM, Suntharalingam M, Donahue J, Nagib M, Carr SR, Friedberg J, Badiyan S, Simone CB, et al. Corrigendum to "Clinical outcomes of black vs. non-black patients with locally advanced non-small cell lung cancer" [Lung Cancer 114, (December 2017) 44-49]. Lung Cancer (Amsterdam, Netherlands). PMID 29289353 DOI: 10.1016/J.Lungcan.2017.12.011 |
0.308 |
|
| 2017 |
Edelman MJ, Hu C, Le QT, Donington JS, D'Souza WD, Dicker AP, Loo BW, Gore EM, Videtic GMM, Evans NR, Leach JW, Diehn M, Feigenberg SJ, Chen Y, Paulus R, et al. Randomized Phase II Study of Preoperative Chemoradiotherapy +/- Panitumumab Followed by Consolidation Chemotherapy in Potentially Operable Locally Advanced (Stage IIIa, N2+) Non-small Cell Lung Cancer: NRG Oncology RTOG 0839. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. PMID 28629896 DOI: 10.1016/J.Jtho.2017.06.007 |
0.323 |
|
| 2017 |
Edelman MJ, Wang X, Hodgson L, Cheney RT, Baggstrom MQ, Sachdev T, Gajra A, Bertino EM, Reckamp KL, Molina J, Schiller J, Mitchell-Edwards K, Friedman P, Ritter J, Milne G, et al. Final Results of a Phase 3 Trial of Celecoxib (C) in Addition to Standard Chemotherapy for Advanced Non-Small Cell Lung Cancer With COX- 2 Overexpression: CALGB 30801 (Alliance). International Journal of Radiation Oncology, Biology, Physics. 98: 220-221. PMID 28586968 DOI: 10.1016/J.Ijrobp.2017.01.038 |
0.333 |
|
| 2017 |
Scilla KA, Bentzen SM, Lam VK, Mohindra P, Nichols EM, Vyfhuis MA, Bhooshan N, Feigenberg SJ, Edelman MJ, Feliciano JL. Neutrophil-Lymphocyte Ratio Is a Prognostic Marker in Patients with Locally Advanced (Stage IIIA and IIIB) Non-Small Cell Lung Cancer Treated with Combined Modality Therapy. The Oncologist. PMID 28533476 DOI: 10.1634/Theoncologist.2016-0443 |
0.314 |
|
| 2017 |
Edelman MJ, Wang X, Hodgson L, Cheney RT, Baggstrom MQ, Thomas SP, Gajra A, Bertino E, Reckamp KL, Molina J, Schiller JH, Mitchell-Richards K, Friedman PN, Ritter J, Milne G, et al. Phase III Randomized, Placebo-Controlled, Double-Blind Trial of Celecoxib in Addition to Standard Chemotherapy for Advanced Non-Small-Cell Lung Cancer With Cyclooxygenase-2 Overexpression: CALGB 30801 (Alliance). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2016713743. PMID 28489511 DOI: 10.1200/Jco.2016.71.3743 |
0.311 |
|
| 2017 |
Baggstrom MQ, Socinski MA, Wang XF, Gu L, Stinchcombe TE, Edelman MJ, Baker S, Feliciano J, Novotny P, Hahn O, Crawford JA, Vokes EE. Maintenance Sunitinib following Initial Platinum-Based Combination Chemotherapy in Advanced Stage IIIB/IV Non-small cell Lung Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase III Study - CALGB 30607 (Alliance). Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. PMID 28161554 DOI: 10.1016/j.jtho.2017.01.022 |
0.354 |
|
| 2017 |
Chaft JE, Dahlberg SE, Gerber DE, Oxnard GR, Malik SM, Simone CB, Edelman MJ, Heymach J, Rudin CM, Ramalingam SS. EA5142 adjuvant nivolumab in resected lung cancers (ANVIL): The newest study in the ALCHEMIST platform. Journal of Clinical Oncology. 35: TPS8575-TPS8575. DOI: 10.1200/JCO.2017.35.15_SUPPL.TPS8575 |
0.312 |
|
| 2017 |
Daniel D, Rudin C, Hart L, Spigel D, Edelman M, Goldschmidt J, Bordoni R, Glisson B, Burns T, Dowlati A, Dy G, Beck T, Jotte R, Liu S, Kapoun A, et al. Results of a randomized, placebo-controlled, phase 2 study of tarextumab (TRXT, anti-Notch2/3) in combination with etoposide and platinum (EP) in patients (pts) with untreated extensive-stage small-cell lung cancer (ED-SCLC) Annals of Oncology. 28: v540. DOI: 10.1093/ANNONC/MDX386.004 |
0.318 |
|
| 2017 |
Vyfhuis M, Bhooshan N, Molitoris J, Burrows W, Edelman M, Nichols E, Suntharalingam M, Donahue J, Feliciano J, Badiyan S, Carr S, Friedberg J, Feigenberg S, Mohindra P. Black Patients with Locally Advanced Non-small Cell Lung Cancer: An Inclusive Multimodality Approach is Justified International Journal of Radiation Oncology*Biology*Physics. 99: S210. DOI: 10.1016/J.IJROBP.2017.06.519 |
0.307 |
|
| 2017 |
Melissa V, Bhooshan N, Molitoris J, Edelman M, Burrows W, Nichols E, Suntharalingam M, Donahue J, Shamus C, Friedberg J, Badiyan S, Feliciano J, Feigenberg S, Mohindra P. (P082) Black Patients With Locally Advanced Non-Small Cell Lung Cancer (LA- NSCLC) - An Inclusive Multi-Modality Approach Is Justified International Journal of Radiation Oncology*Biology*Physics. 98: E37. DOI: 10.1016/J.IJROBP.2017.02.178 |
0.306 |
|
| 2017 |
Rice SR, Vyfhuis M, Neha B, Edelman MJ, Burrows W, Nichols EM, Suntharalingam M, Donahue J, Carr S, Joseph F, Badiyan SN, Feliciano J, Feigenberg SJ, Mohindra P. (S011) Does Insurance Status Impact Survival Outcomes in Patients With Stage III Non-Small Cell Lung Cancer (NSCLC) Treated With Curative Intent? International Journal of Radiation Oncology*Biology*Physics. 98: E4. DOI: 10.1016/J.IJROBP.2017.02.047 |
0.323 |
|
| 2016 |
Spigel DR, Edelman MJ, O'Byrne K, Paz-Ares L, Mocci S, Phan S, Shames DS, Smith D, Yu W, Paton VE, Mok T. Results From the Phase III Randomized Trial of Onartuzumab Plus Erlotinib Versus Erlotinib in Previously Treated Stage IIIB or IV Non-Small-Cell Lung Cancer: METLung. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2016692160. PMID 27937096 DOI: 10.1200/Jco.2016.69.2160 |
0.304 |
|
| 2016 |
Edelman MJ, Hu C, Le Q, Donington J, D'Souza WD, Dicker A, Loo BW, Gore E, Videtic GM, Evans NR, Leach J, Diehn M, Feigenberg SJ, Chen Y, Bradley JD. Randomized phase II study of preoperative chemoradiotherapy (CRT)+/- Panitumumab (P) followed by consolidation chemotherapy (C) in potentially operable locally advanced (stage IIIa, N2+) non-small cell lung cancer (LANSCLC): Nrg oncology/RTOG 0839. Journal of Clinical Oncology. 34: 8510-8510. DOI: 10.1200/Jco.2016.34.15_Suppl.8510 |
0.306 |
|
| 2015 |
Edelman MJ, Tan MT, Fidler MJ, Sanborn RE, Otterson G, Sequist LV, Evans TL, Schneider BJ, Keresztes R, Rogers JS, de Mayolo JA, Feliciano J, Yang Y, Medeiros M, Zaknoen SL. Randomized, double-blind, placebo-controlled, multicenter phase II study of the efficacy and safety of apricoxib in combination with either docetaxel or pemetrexed in patients with biomarker-selected non-small-cell lung cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 33: 189-94. PMID 25452446 DOI: 10.1200/JCO.2014.55.5789 |
0.322 |
|
| 2015 |
Feliciano J, Gardner L, Hendrick F, Edelman MJ, Davidoff A. Assessing functional status and the survival benefit of chemotherapy for advanced non-small cell lung cancer using administrative claims data Lung Cancer. 87: 59-64. DOI: 10.1016/j.lungcan.2014.10.011 |
0.321 |
|
| 2015 |
Bhooshan N, Edelman M, Nichols E, Liriano M, Feliciano J, Burrows W, Suntharalingam M, D'Souza W, Vujaskovic Z, Feigenberg S, Mohindra P. Does Severe Radiation Pneumonitis (RP) Affect Clinical Outcomes in Nonoperable Stage III Non-Small Cell Lung Cancer (NSCLC) Patients Treated With Carboplatin/Paclitaxel (CP)-based Concurrent Chemoradiation Therapy (CRT)? International Journal of Radiation Oncology*Biology*Physics. 93: S151. DOI: 10.1016/J.Ijrobp.2015.07.359 |
0.314 |
|
| 2014 |
Wakelee H, Kelly K, Edelman MJ. 50 Years of progress in the systemic therapy of non-small cell lung cancer. American Society of Clinical Oncology Educational Book / Asco. American Society of Clinical Oncology. Meeting. 177-89. PMID 24857075 DOI: 10.14694/EdBook_AM.2014.34.177 |
0.315 |
|
| 2014 |
Kerr KM, Bubendorf L, Edelman MJ, Marchetti A, Mok T, Novello S, O'Byrne K, Stahel R, Peters S, Felip E. Second ESMO consensus conference on lung cancer: pathology and molecular biomarkers for non-small-cell lung cancer. Annals of Oncology : Official Journal of the European Society For Medical Oncology / Esmo. 25: 1681-90. PMID 24718890 DOI: 10.1093/Annonc/Mdu145 |
0.324 |
|
| 2014 |
Stephenson JJ, Nemunaitis J, Joy AA, Martin JC, Jou YM, Zhang D, Statkevich P, Yao SL, Zhu Y, Zhou H, Small K, Bannerji R, Edelman MJ. Randomized phase 2 study of the cyclin-dependent kinase inhibitor dinaciclib (MK-7965) versus erlotinib in patients with non-small cell lung cancer. Lung Cancer (Amsterdam, Netherlands). 83: 219-23. PMID 24388167 DOI: 10.1016/j.lungcan.2013.11.020 |
0.309 |
|
| 2014 |
Chiappori A, Williams C, Northfelt DW, Adams JW, Malik S, Edelman MJ, Rosen P, Van Echo DA, Berger MS, Haura EB. Obatoclax mesylate, a pan-bcl-2 inhibitor, in combination with docetaxel in a phase 1/2 trial in relapsed non-small-cell lung cancer. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 9: 121-5. PMID 24346101 DOI: 10.1097/JTO.0000000000000027 |
0.333 |
|
| 2014 |
Socinski MA, Wang XF, Baggstrom MQ, Gu L, Stinchcombe TE, Edelman MJ, Baker JR S, Mannuel HD, Crawford J, Vokes EE. Sunitinib (S) switch maintenance in advanced non-small cell lung cancer (NSCLC): An ALLIANCE (CALGB 30607), randomized, placebo-controlled phase III trial. Journal of Clinical Oncology. 32: 8040-8040. DOI: 10.1200/JCO.2014.32.15_SUPPL.8040 |
0.318 |
|
| 2014 |
Socinski M, Wang X, Baggstrom M, Gu L, Stinchcombe T, Edelman M, Baker S, Mannuel H, Crawford J, Vokes E. Switch Maintenance With Sunitinib (S) in Advanced Non-Small Cell Lung Cancer (NSCLC): An Alliance (CALGB 30607), Randomized, Placebo-Controlled Phase 3 Trial International Journal of Radiation Oncology*Biology*Physics. 90: S1. DOI: 10.1016/J.IJROBP.2014.08.022 |
0.31 |
|
| 2013 |
Goss GD, O'Callaghan C, Lorimer I, Tsao MS, Masters GA, Jett J, Edelman MJ, Lilenbaum R, Choy H, Khuri F, Pisters K, Gandara D, Kernstine K, Butts C, Noble J, et al. Gefitinib versus placebo in completely resected non-small-cell lung cancer: results of the NCIC CTG BR19 study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 31: 3320-6. PMID 23980091 DOI: 10.1200/Jco.2013.51.1816 |
0.34 |
|
| 2013 |
Kelly K, Chansky K, Mack PC, Lara PN, Hirsch FR, Franklin WA, Wozniak AJ, Edelman MJ, Williamson SK, Gandara DR. Chemotherapy outcomes by histologic subtypes of non-small-cell lung cancer: analysis of the southwest oncology group database for antimicrotubule-platinum therapy. Clinical Lung Cancer. 14: 627-35. PMID 23910067 DOI: 10.1016/j.cllc.2013.06.010 |
0.351 |
|
| 2013 |
Edelman MJ, Schneider CP, Tsai CM, Kim HT, Quoix E, Luft AV, Kaleta R, Mukhopadhyay P, Trifan OC, Whitaker L, Reck M. Randomized phase II study of ixabepilone or paclitaxel plus carboplatin in patients with non-small-cell lung cancer prospectively stratified by beta-3 tubulin status. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 31: 1990-6. PMID 23589560 DOI: 10.1200/JCO.2012.45.3282 |
0.315 |
|
| 2012 |
Edelman MJ, Le Chevalier T, Soria JC. Maintenance therapy and advanced non-small-cell lung cancer: a skeptic's view. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 7: 1331-6. PMID 22895137 DOI: 10.1097/JTO.0b013e3182629e37 |
0.338 |
|
| 2012 |
Jänne PA, Wang X, Socinski MA, Crawford J, Stinchcombe TE, Gu L, Capelletti M, Edelman MJ, Villalona-Calero MA, Kratzke R, Vokes EE, Miller VA. Randomized phase II trial of erlotinib alone or with carboplatin and paclitaxel in patients who were never or light former smokers with advanced lung adenocarcinoma: CALGB 30406 trial. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 30: 2063-9. PMID 22547605 DOI: 10.1200/JCO.2011.40.1315 |
0.329 |
|
| 2012 |
Edelman MJ, Hodgson L, Rosenblatt PY, Christenson RH, Vokes EE, Wang X, Kratzke R. CYFRA 21-1 as a prognostic and predictive marker in advanced non-small-cell lung cancer in a prospective trial: CALGB 150304. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 7: 649-54. PMID 22425913 DOI: 10.1097/JTO.0b013e31824a8db0 |
0.347 |
|
| 2012 |
Edelman MJ, Shvartsbeyn M. Epothilones in development for non--small-cell lung cancer: novel anti-tubulin agents with the potential to overcome taxane resistance. Clinical Lung Cancer. 13: 171-80. PMID 22133291 DOI: 10.1016/j.cllc.2011.02.005 |
0.324 |
|
| 2012 |
Liriano M, Nichols E, Morris C, Burrows W, Battafarano R, Garofalo M, Turner M, Suntharalingam M, Edelman M, Feigenberg S. Trimodality Therapy for Locally Advanced Non-small Cell Lung Cancer (NSCLC): Predictors of Surgical Drop Out International Journal of Radiation Oncology*Biology*Physics. 84: S173-S174. DOI: 10.1016/J.IJROBP.2012.07.450 |
0.307 |
|
| 2012 |
Nichols E, Liriano M, Morris C, Burrows W, Battafarano R, Garofalo M, Turner M, Suntharalingam M, Edelman M, Feigenberg S. Marital Status Is an Independent Predictor of Survival for Patients Undergoing Definitive Chemoradiation for Stage III Non-small Cell Lung Cancer (NSCLC) International Journal of Radiation Oncology*Biology*Physics. 84: S566-S567. DOI: 10.1016/J.IJROBP.2012.07.1509 |
0.332 |
|
| 2011 |
Davidoff AJ, Gardner JF, Seal B, Edelman MJ. Population-based estimates of survival benefit associated with combined modality therapy in elderly patients with locally advanced non-small cell lung cancer. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 6: 934-41. PMID 21372743 DOI: 10.1097/JTO.0b013e31820eed00 |
0.306 |
|
| 2011 |
Edelman MJ, Otterson G, Leach J, Malpass T, Salgia R, Jones D, Mody TD, Govindan R. Multicenter phase II trial of Motexafin gadolinium and pemetrexed for second-line treatment in patients with non-small cell lung cancer. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 6: 786-9. PMID 21289521 DOI: 10.1097/Jto.0B013E31820A443F |
0.319 |
|
| 2011 |
Ansari RH, Socinski MA, Edelman MJ, Belani CP, Gonin R, Catalano RB, Marinucci DM, Comis RL, Obasaju CK, Chen R, Monberg MJ, Treat J. A retrospective analysis of outcomes by age in a three-arm phase III trial of gemcitabine in combination with carboplatin or paclitaxel vs. paclitaxel plus carboplatin for advanced non-small cell lung cancer. Critical Reviews in Oncology/Hematology. 78: 162-71. PMID 20413322 DOI: 10.1016/j.critrevonc.2010.03.003 |
0.36 |
|
| 2010 |
Davidoff AJ, Tang M, Seal B, Edelman MJ. Chemotherapy and survival benefit in elderly patients with advanced non-small-cell lung cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 28: 2191-7. PMID 20351329 DOI: 10.1200/JCO.2009.25.4052 |
0.339 |
|
| 2010 |
Treat J, Edelman MJ, Belani CP, Socinski MA, Monberg MJ, Chen R, Obasaju CK. A retrospective analysis of outcomes across histological subgroups in a three-arm phase III trial of gemcitabine in combination with carboplatin or paclitaxel versus paclitaxel plus carboplatin for advanced non-small cell lung cancer. Lung Cancer (Amsterdam, Netherlands). 70: 340-6. PMID 20347506 DOI: 10.1016/j.lungcan.2010.02.011 |
0.344 |
|
| 2010 |
Krasna MJ, Gamliel Z, Burrows WM, Sonett JR, Kwong KF, Edelman MJ, Hausner PF, Doyle LA, DeYoung C, Suntharalingam M. Pneumonectomy for lung cancer after preoperative concurrent chemotherapy and high-dose radiation. The Annals of Thoracic Surgery. 89: 200-6; discussion 20. PMID 20103235 DOI: 10.1016/j.athoracsur.2009.08.069 |
0.316 |
|
| 2010 |
Edelman MJ, Belani CP, Socinski MA, Ansari RH, Obasaju CK, Chen R, Monberg MJ, Treat J. Outcomes associated with brain metastases in a three-arm phase III trial of gemcitabine-containing regimens versus paclitaxel plus carboplatin for advanced non-small cell lung cancer. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 5: 110-6. PMID 20035187 DOI: 10.1097/JTO.0b013e3181c59a3a |
0.34 |
|
| 2010 |
Treat JA, Gonin R, Socinski MA, Edelman MJ, Catalano RB, Marinucci DM, Ansari R, Gillenwater HH, Rowland KM, Comis RL, Obasaju CK, Belani CP. A randomized, phase III multicenter trial of gemcitabine in combination with carboplatin or paclitaxel versus paclitaxel plus carboplatin in patients with advanced or metastatic non-small-cell lung cancer. Annals of Oncology : Official Journal of the European Society For Medical Oncology / Esmo. 21: 540-7. PMID 19833819 DOI: 10.1093/annonc/mdp352 |
0.359 |
|
| 2009 |
Ansari RH, Edelman MJ, Belani CP, Socinski MA, Obasaju CK, Monberg MJ, Chen R, Treat J. Outcomes for the elderly (≥70 years) from a three-arm phase III trial of gemcitabine in combination with carboplatin (GC) or paclitaxel (GP) versus paclitaxel plus carboplatin (PC) for advanced non-small cell lung cancer (NSCLC). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 8052. PMID 27962865 DOI: 10.1200/jco.2009.27.15_suppl.8052 |
0.307 |
|
| 2009 |
Edelman MJ, Belani CP, Socinski MA, Ansari R, Obasaju CK, Monberg MJ, Chen R, Treat J. Incidence and outcomes associated with brain metastases (BM) in a three-arm phase III trial of gemcitabine in combination with carboplatin (GC) or paclitaxel (GP) versus paclitaxel plus carboplatin (PC) for advanced non-small cell lung cancer (NSCLC). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 8076. PMID 27962650 DOI: 10.1200/jco.2009.27.15_suppl.8076 |
0.339 |
|
| 2009 |
Wakelee H, Loo BW, Kernstine KH, Putnam JB, Edelman MJ, Vokes EE, Schiller JH, Baas P, Saijo N, Adjei A, Goss G, Choy H, Gandara DR. Cooperative group research efforts in thoracic malignancies 2009: a review from the 10th Annual International Lung Cancer Congress. Clinical Lung Cancer. 10: 395-404. PMID 19900856 DOI: 10.3816/Clc.2009.N.075 |
0.312 |
|
| 2009 |
Rivera MP, Detterbeck FC, Socinski MA, Moore DT, Edelman MJ, Jahan TM, Ansari RH, Luketich JD, Peng G, Monberg M, Obasaju CK, Gralla RJ. Impact of preoperative chemotherapy on pulmonary function tests in resectable early-stage non-small cell lung cancer. Chest. 135: 1588-95. PMID 19188545 DOI: 10.1378/chest.08-1430 |
0.314 |
|
| 2009 |
Neuner G, VanderWalde N, Goulobeva O, Suntharalingam M, Battafarano R, Burrows W, Edelman M, Schuetz J, Dhople A. The Effect of Pathological Response on Survival in Patients undergoing Trimodality Therapy for Surgically Staged N2 Non–small Cell Lung Cancer (NSCLC) International Journal of Radiation Oncology*Biology*Physics. 75: S438-S439. DOI: 10.1016/J.IJROBP.2009.07.1004 |
0.306 |
|
| 2008 |
Miller AA, Wang XF, Gu L, Hoffman P, Khatri J, Dunphy F, Edelman MJ, Bolger M, Vokes EE, Green MR. Phase II randomized study of dose-dense docetaxel and cisplatin every 2 weeks with pegfilgrastim and darbepoetin alfa with and without the chemoprotector BNP7787 in patients with advanced non-small cell lung cancer (CALGB 30303). Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 3: 1159-65. PMID 18827613 DOI: 10.1097/JTO.0b013e318186fb0d |
0.333 |
|
| 2008 |
Edelman MJ, Watson D, Wang X, Morrison C, Kratzke RA, Jewell S, Hodgson L, Mauer AM, Gajra A, Masters GA, Bedor M, Vokes EE, Green MJ. Eicosanoid modulation in advanced lung cancer: cyclooxygenase-2 expression is a positive predictive factor for celecoxib + chemotherapy--Cancer and Leukemia Group B Trial 30203. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 848-55. PMID 18281656 DOI: 10.1200/JCO.2007.13.8081 |
0.326 |
|
| 2008 |
Detterbeck FC, Socinski MA, Gralla RJ, Edelman MJ, Jahan TM, Loesch DM, Limentani SA, Govindan R, Zaman MB, Ye Z, Monberg MJ, Obasaju CK. Neoadjuvant chemotherapy with gemcitabine-containing regimens in patients with early-stage non-small cell lung cancer. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 3: 37-45. PMID 18166839 DOI: 10.1097/JTO.0b013e31815e5d9a |
0.345 |
|
| 2008 |
Chiappori A, Williams C, Northfelt D, Adams J, Malik S, Edelman M, Rosen P, Van Echo D, Berger M, Haura E. 592 POSTER Obatoclax (GX17–070), a small molecule pan-bcl-2 inhibitor, in combination with docetaxel in a phase I/II trial enrolling patients with relapsed non-small cell lung cancer (NSCLC) European Journal of Cancer Supplements. 6: 185. DOI: 10.1016/S1359-6349(08)72526-6 |
0.334 |
|
| 2007 |
Lustberg MB, Edelman MJ. Optimal duration of chemotherapy in advanced non-small cell lung cancer. Current Treatment Options in Oncology. 8: 38-46. PMID 17634834 DOI: 10.1007/s11864-007-0020-6 |
0.314 |
|
| 2007 |
Vansteenkiste J, Lara PN, Le Chevalier T, Breton JL, Bonomi P, Sandler AB, Socinski MA, Delbaldo C, McHenry B, Lebwohl D, Peck R, Edelman MJ, Edelman M. Phase II clinical trial of the epothilone B analog, ixabepilone, in patients with non small-cell lung cancer whose tumors have failed first-line platinum-based chemotherapy. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 25: 3448-55. PMID 17606973 DOI: 10.1200/JCO.2006.09.7097 |
0.347 |
|
| 2007 |
Natale R, Nicholas G, Pandya K, Edelman M, Phan S, Renschler M. Motexafin Gadolinium (MGd) is Active as a Single Agent and in Combination with Pemetrexed and Docetaxel in Advanced Non–Small-Cell Lung Cancer (NSCLC) Patients who Failed Platinum-Based Chemotherapy: Early Results of 3 Phase II Trials Clinical Lung Cancer. 8: 455. DOI: 10.1016/S1525-7304(11)70820-8 |
0.346 |
|
| 2007 |
Patel A, Edelman M, Burrows W, Hausner P, Kwok Y, Krasna M, Suntharalingam M. The Impact of Prophylactic Cranial Irradiation in Patients With Locally Advanced Non-Small Cell Lung Cancer Treated With Trimodality Therapy International Journal of Radiation Oncology*Biology*Physics. 69: S162-S163. DOI: 10.1016/J.IJROBP.2007.07.293 |
0.317 |
|
| 2006 |
Edelman MJ. Novel Cytotoxic Agents for Non-small Cell Lung Cancer Journal of Thoracic Oncology. 1: 752-755. DOI: 10.1016/S1556-0864(15)30400-7 |
0.305 |
|
| 2005 |
Edelman MJ, Bisaccia S, Smith R, Lesko S, Lum ZP, Ts'o PO. Circulating cancer cells (CCC) in non-small cell lung cancer (NSCLC): incidence and preliminary observations on prognostic significance and potential for individualized therapy. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 23: 7205. PMID 27944638 DOI: 10.1200/jco.2005.23.16_suppl.7205 |
0.317 |
|
| 2005 |
Edelman MJ. The potential role of bortezomib in combination with chemotherapy and radiation in non-small-cell lung cancer. Clinical Lung Cancer. 7: S64-6. PMID 16250930 DOI: 10.3816/CLC.2005.S.011 |
0.316 |
|
| 2005 |
Edelman MJ, Smith R, Hausner P, Doyle LA, Kalra K, Kendall J, Bedor M, Bisaccia S. Phase II trial of the novel retinoid, bexarotene, and gemcitabine plus carboplatin in advanced non-small-cell lung cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 23: 5774-8. PMID 16110034 DOI: 10.1200/JCO.2005.14.373 |
0.35 |
|
| 2005 |
Treat J, Belani CP, Edelman MJ, Socinski MA, Ansari RH, Obasaju CK, Bloss JD, Marinucci DM, Catalano RB, Comis RL. A randomized phase III trial of gemcitabine (G) in combination with carboplatin (C) or paclitaxel (P) versus paclitaxel plus carboplatin in advanced (Stage IIIB, IV) non-small cell lung cancer (NSCLC): Update of the Alpha Oncology trial (A1–99002L) Journal of Clinical Oncology. 23: LBA7025-LBA7025. DOI: 10.1200/JCO.2005.23.16_SUPPL.LBA7025 |
0.301 |
|
| 2005 |
Suntharalingam M, Edelman MJ, Kwong K, Smith R, Bedor M. Phase I trial of proteasome inhibition with bortezomib (BOR) with concurrent chemoradiation (chemoXRT) for stage III non-small cell lung cancer (NSCLC) Journal of Clinical Oncology. 23: 7300-7300. DOI: 10.1200/JCO.2005.23.16_SUPPL.7300 |
0.333 |
|
| 2005 |
Detterbeck FC, Socinski MA, Gralla RJ, Edelman MJ, Jahan TM, Loesch DM, Limentani SA, Govindan R, Bloss LP, Obasaju CK. Neoadjuvant chemotherapy with gemcitabine-containing regimens in patients with early stage non-small cell lung cancer (NSCLC): Initial results of the GINEST • project Journal of Clinical Oncology. 23: 7215-7215. DOI: 10.1200/JCO.2005.23.16_SUPPL.7215 |
0.321 |
|
| 2005 |
Papadimitrakopoulou V, Edelman M, Zinner R, Blumenschein G, Jones S, Willcutt N, Keck J, Brown G, Burris H. P-550 Phase 1–2 dose-ranging trial of TLK286 (TELCYTA) and Cisplatin (C) as first-line treatment in advanced non-small cell lung cancer (NSCLC) Lung Cancer. 49: S262. DOI: 10.1016/S0169-5002(05)81043-8 |
0.311 |
|
| 2004 |
Le QT, McCoy J, Williamson S, Ryu J, Gaspar LE, Edelman MJ, Dakhil SR, Sides SD, Crowley JJ, Gandara DR. Phase I study of tirapazamine plus cisplatin/etoposide and concurrent thoracic radiotherapy in limited-stage small cell lung cancer (S0004): a Southwest Oncology Group study. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 10: 5418-24. PMID 15328179 DOI: 10.1158/1078-0432.CCR-04-0436 |
0.327 |
|
| 2004 |
Edelman MJ, Clark JI, Chansky K, Albain K, Bhoopalam N, Weiss GR, Giguere JK, Kelly K, Crowley J, Gandara DR. Randomized phase II trial of sequential chemotherapy in advanced non-small cell lung cancer (SWOG 9806): carboplatin/gemcitabine followed by paclitaxel or cisplatin/vinorelbine followed by docetaxel. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 10: 5022-6. PMID 15297403 DOI: 10.1158/1078-0432.CCR-04-0002 |
0.342 |
|
| 2004 |
Edelman MJ. Gemcitabine and carboplatin regimens in advanced non-small-cell lung cancer: focus on randomized phase III trials. Clinical Lung Cancer. S40-4. PMID 14870715 DOI: 10.3816/CLC.2003.S.002 |
0.321 |
|
| 2004 |
Edelman MJ, Chansky K, Gaspar LE, Leigh B, Weiss GR, Taylor SA, Crowley J, Livingston R, Gandara DR. Phase II trial of cisplatin/etoposide and concurrent radiotherapy followed by paclitaxel/carboplatin consolidation for limited small-cell lung cancer: Southwest Oncology Group 9713. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 22: 127-32. PMID 14701775 DOI: 10.1200/JCO.2004.06.070 |
0.345 |
|
| 2003 |
Edelman MJ, Gandara DR, Hausner P, Israel V, Thornton D, DeSanto J, Doyle LA. Phase 2 study of cryptophycin 52 (LY355703) in patients previously treated with platinum based chemotherapy for advanced non-small cell lung cancer. Lung Cancer (Amsterdam, Netherlands). 39: 197-9. PMID 12581573 DOI: 10.1016/S0169-5002(02)00511-1 |
0.342 |
|
| 2003 |
Treat J, Chandra BP, Edelman M, Socinski M, Gonin R, Ansari R, Gillenwater H, Rogers J, Obasaju C, Comis R. O-217 A randomized phase III trial of gemcitabine (G) in combination with carboplatin (C) or paclitaxel (P) versus paclitaxel plus carboplatin in advanced (Stage IIIB, IV) Non-Small Cell Lung Cancer (NSCLC) Lung Cancer. 41: S64. DOI: 10.1016/S0169-5002(03)91875-7 |
0.312 |
|
| 2003 |
Edelman MJ, Breton JL, Sandler A, Lara P, Bonomil P, LeChevalier T, Ardizzoni A, Paz-Ares L, Peck R, Vansteenkiste J. O-3 Randomized phase II study of the novel tubulin targetin agent, BMS-247550 (Epothilone B analogue) in the treatment of non-small cell lung cancer (NSCLC) in patients (pts) who have failed first line platinum containing therapy Lung Cancer. 41: S5. DOI: 10.1016/S0169-5002(03)91661-8 |
0.317 |
|
| 2002 |
Edelman MJ. Neoadjuvant chemotherapy in early-stage non-small cell lung cancer. Expert Review of Anticancer Therapy. 1: 229-35. PMID 12113028 DOI: 10.1586/14737140.1.2.229 |
0.338 |
|
| 2002 |
Edelman MJ, Khanwani SL. Advanced non-small cell lung cancer. Current Treatment Options in Oncology. 2: 51-62. PMID 12057140 DOI: 10.1007/S11864-001-0016-6 |
0.315 |
|
| 2001 |
Edelman MJ, Gandara DR, Lau DH, Lara P, Lauder IJ, Tracy D. Sequential combination chemotherapy in patients with advanced nonsmall cell lung carcinoma: carboplatin and gemcitabine followed by paclitaxel. Cancer. 92: 146-52. PMID 11443620 DOI: 10.1002/1097-0142(20010701)92:1<146::AID-CNCR1302>3.0.CO;2-N |
0.312 |
|
| 2001 |
Lau D, Leigh B, Gandara D, Edelman M, Morgan R, Israel V, Lara P, Wilder R, Ryu J, Doroshow J. Twice-weekly paclitaxel and weekly carboplatin with concurrent thoracic radiation followed by carboplatin/paclitaxel consolidation for stage III non-small-cell lung cancer: a California Cancer Consortium phase II trial. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 19: 442-7. PMID 11208837 DOI: 10.1200/jco.2001.19.2.442 |
0.349 |
|
| 2001 |
Edelman MJ. New directions in the treatment of non-small cell lung cancer: an overview. The Oncologist. 1-3. PMID 11181996 DOI: 10.1634/THEONCOLOGIST.6-SUPPL_1-1 |
0.317 |
|
| 2001 |
Edelman MJ. Commentary on “Phase II Study of Sequential Treatment of Advanced Non–Small-Cell Lung Cancer: Three Cycles of High-Dose Epirubicin Plus Cisplatin Followed by Weekly Vinorelbine” Clinical Lung Cancer. 3: 47-48. DOI: 10.1016/S1525-7304(11)70753-7 |
0.302 |
|
| 2001 |
Treat J, Huang C, Damanjov N, Jahanzeb M, Edelman M, Koehler M. ZD0473 phase II monotherapy trial in second-line non-small cell lung cancer European Journal of Cancer. 37: S59-S60. DOI: 10.1016/S0959-8049(01)80701-2 |
0.314 |
|
| 2000 |
Lau D, Ryu J, Gandara D, Edelman M, Israel V, Doroshow J. A California Cancer Consortium phase II trial of concurrent twice-weekly paclitaxel, weekly carboplatin and radiation followed by paclitaxel/carboplatin consolidation for stage III non-small-cell lung cancer Lung Cancer. 29: 111. DOI: 10.1016/S0169-5002(00)80367-0 |
0.329 |
|
| 2000 |
Lara P, Law L, Reddy G, Edelman M, Doroshow J, Lau D, Lenz H, Israel V, Albain K, Jaslowski A, Longmate J, Frankel P, Gandara D. Salvage gemcitabine (GEM) in platinum-treated non-small cell lung cancer (NSCLC): A phase II California cancer consortium trial Lung Cancer. 29: 58. DOI: 10.1016/S0169-5002(00)80187-7 |
0.345 |
|
| 2000 |
Edelman M, Gandara D, Lau D, Lara P, Lauder I. Sequential chemotherapy with carboplatin (C) and gemcitabine (G) followed by paclitaxel (P) in poor performance status (PS) and elderly patients (pts) with non-small cell lung cancer (NSCLC) Lung Cancer. 29: 16-17. DOI: 10.1016/S0169-5002(00)80049-5 |
0.312 |
|
| 1997 |
Gandara DR, Edelman MJ, Crowley JJ, Lau DH, Livingston RB. Phase II trial of edatrexate plus carboplatin in metastatic non-small-cell lung cancer: a Southwest Oncology Group study. Cancer Chemotherapy and Pharmacology. 41: 75-8. PMID 9443617 DOI: 10.1007/S002800050710 |
0.305 |
|
| 1996 |
Edelman MJ, Gandara DR, Roach M, Benfield JR. Multimodality therapy in stage III non-small cell lung cancer. The Annals of Thoracic Surgery. 61: 1564-72. PMID 8633990 DOI: 10.1016/0003-4975(96)00044-6 |
0.328 |
|
| 1996 |
Edelman MJ, Gandara DR. Promising new agents in the treatment of non-small cell lung cancer. Cancer Chemotherapy and Pharmacology. 37: 385-93. PMID 8599859 DOI: 10.1007/s002800050402 |
0.32 |
|
| Show low-probability matches. |